{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:03:07Z","timestamp":1790402587428,"version":"4.1.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Roflumilast has approved treatment in patients with chronic obstructive pulmonary disease. The post-marketing data concerning roflumilast remain limited, and the outcomes of relevant studies are yet to yield conclusive evidence supporting the long-term psychiatric safety of roflumilast.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This investigation comprehensively assessed psychiatric adverse events (AEs) attributed to roflumilast by employing data mining techniques, utilizing the FDA Adverse Event Reporting System (FAERS). The dataset encompasses the period from the first quarter of 2014 to the first quarter of 2025.\u00a0A disproportionality analysis was conducted to quantify the correlation between roflumilast and psychiatric AEs. The metrics employed for the evaluation of disproportionality comprise the reporting odds ratio (ROR), the proportional reporting ratio, the information component, and the empirical Bayesian geometric mean.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 414 reports were identified as related to psychiatric AEs of roflumilast, with the identification of 31 preferred terms. Five of psychiatric AEs exhibited significant positive signals, including insomnia (ROR 3.55), suicidal ideation (ROR 4.32), sleep disorder due to a general medical condition (ROR 13.47), nervousness (ROR 3.30), and eating disorder (ROR 5.16). A relatively increases risk of life-threatening and hospitalization in psychiatric AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings would provide valued evidence for healthcare professionals to recognize psychiatric AEs associated with roflumilast and guide their clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1836593","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:48:48Z","timestamp":1781156928000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Psychiatric events induced by roflumilast: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System database"],"prefix":"10.3389","volume":"17","author":[{"given":"Lifang","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Second Affiliated Hospital of Xiamen Medical College","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pingtan Comprehensive Experimental Area Hospital, Pingtan Comprehensive Experimental Area","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojun","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]},{"name":"Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/copd.S419828","article-title":"Glucocorticoid alleviates mechanical stress-induced airway inflammation and remodeling in COPD via transient receptor potential canonical 1 channel","volume":"18","author":"Wu","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102813","article-title":"Cellular senescence in chronic obstructive pulmonary disease: molecular mechanisms and therapeutic interventions","volume":"110","author":"Subedi","year":"2025","journal-title":"Ageing Res Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.12659\/msm.942672","article-title":"Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 guidelines for COPD, including COVID-19, climate change, and air pollution","volume":"29","author":"Parums","year":"2023","journal-title":"Med Sci Monit"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/copd.S176122","article-title":"Role of inflammatory cells in airway remodeling in COPD","volume":"13","author":"Wang","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3565(24)29538-0","article-title":"In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor","volume":"297","author":"Bundschuh","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)29537-9","article-title":"Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro","volume":"297","author":"Hatzelmann","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.307","article-title":"PDE4 inhibitors: current status","volume":"155","author":"Spina","year":"2008","journal-title":"Br J Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.075937","article-title":"Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD","volume":"62","author":"Grootendorst","year":"2007","journal-title":"Thorax"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)62410-7","article-title":"Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial","volume":"385","author":"Martinez","year":"2015","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(05)67100-0","article-title":"Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial","volume":"366","author":"Rabe","year":"2005","journal-title":"Lancet"},{"key":"B13","unstructured":"FDA-label-roflumilast"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0463-1","article-title":"Roflumilast: a review in COPD","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201712-2493OC","article-title":"Determinants of response to roflumilast in severe chronic obstructive pulmonary disease. Pooled analysis of two randomized trials","volume":"198","author":"Martinez","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200610-1563OC","article-title":"Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease","volume":"176","author":"Calverley","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.clinthera.2011.12.008","article-title":"Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease","volume":"34","author":"Pinner","year":"2012","journal-title":"Clin Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"466A","DOI":"10.1378\/chest.10494","article-title":"Characterization of safety with roflumilast, an oral phosphodiesterase-4 inhibitor for the treatment of COPD","volume":"138","author":"Gross","year":"2010","journal-title":"Chest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1753465812466167","article-title":"Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"7","author":"Oba","year":"2013","journal-title":"Ther Adv Respir Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002309.pub6","article-title":"Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease","volume":"5","author":"Janjua","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.8.487","article-title":"Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations","volume":"8","author":"Sakaeda","year":"2011","journal-title":"Int J Med Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0503-6","article-title":"Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles","volume":"37","author":"Michel","year":"2017","journal-title":"Clin Drug Investig"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35193","article-title":"Postmarketing adverse events of tamoxifen in male and female patients with breast cancer","volume":"156","author":"Ke","year":"2025","journal-title":"Int J Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12885-023-11201-w","article-title":"A real-world disproportionality analysis of Rucaparib: post-marketing pharmacovigilance data","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14215","article-title":"Cardiac adverse events associated with quetiapine: disproportionality analysis of FDA adverse event reporting system","volume":"29","author":"Shu","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer","volume":"39","author":"Forbes","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00007813","article-title":"Depression and anxiety in patients with COPD","volume":"23","author":"Yohannes","year":"2014","journal-title":"Eur Respir Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2147\/copd.S123994","article-title":"Recognition, diagnosis, and treatment of cognitive and psychiatric disorders in patients with COPD","volume":"12","author":"Ouellette","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13930","article-title":"Insomnia-a risk factor for mental disorders","volume":"32","author":"Hertenstein","year":"2023","journal-title":"J Sleep Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(20)30136-x","article-title":"Sleep disturbance and psychiatric disorders","volume":"7","author":"Freeman","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2018.10.006","article-title":"Insomnia as a predictor of mental disorders: a systematic review and meta-analysis","volume":"43","author":"Hertenstein","year":"2019","journal-title":"Sleep Med Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104850","article-title":"Insomnia and post-traumatic stress disorder: a meta-analysis on interrelated association (n = 57,618) and prevalence (n = 573,665)","volume":"141","author":"Ahmadi","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.27119","article-title":"Testing bidirectional, longitudinal associations between disturbed sleep and depressive symptoms in children and adolescents using cross-lagged models","volume":"5","author":"Marino","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6446(05)03622-6","article-title":"Keynote review: phosphodiesterase-4 as a therapeutic target","volume":"10","author":"Houslay","year":"2005","journal-title":"Drug Discov Today"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2174\/138161209788168092","article-title":"Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs","volume":"15","author":"Zhang","year":"2009","journal-title":"Curr Pharm Des"},{"key":"B36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1476-5381.2011.01218.x","article-title":"Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease","volume":"163","author":"Rabe","year":"2011","journal-title":"Br J Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1199683","article-title":"Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis","volume":"15","author":"Rogliani","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105314","article-title":"A comprehensive assessment of the association between common drugs and psychiatric disorders using Mendelian randomization and real-world pharmacovigilance database","volume":"107","author":"Chen","year":"2024","journal-title":"EBioMedicine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.01.003","article-title":"Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4)","volume":"25","author":"O'Donnell","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105840","article-title":"The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders","volume":"172","author":"Soca\u0142a","year":"2021","journal-title":"Pharmacol Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042320-014032","article-title":"The gut-brain axis","volume":"73","author":"Mayer","year":"2022","journal-title":"Annu Rev Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gtc.2016.09.007","article-title":"The microbiome-gut-brain axis in health and disease","volume":"46","author":"Dinan","year":"2017","journal-title":"Gastroenterol Clin North Am"},{"key":"B43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/gbb.12109","article-title":"Microbial genes, brain & behaviour - epigenetic regulation of the gut-brain axis","volume":"13","author":"Stilling","year":"2014","journal-title":"Genes Brain Behav"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2013.01.005","article-title":"Gut-brain axis: how the microbiome influences anxiety and depression","volume":"36","author":"Foster","year":"2013","journal-title":"Trends Neurosci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.copbio.2014.10.007","article-title":"Gut brain axis: diet microbiota interactions and implications for modulation of anxiety and depression","volume":"32","author":"Luna","year":"2015","journal-title":"Curr Opin Biotechnol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.12941","article-title":"Psychiatric health risks in North Korean refugee youths resettled in South Korea","volume":"8","author":"Lee","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2025.102111","article-title":"Insomnia and emotion dysregulation: a meta-analytical perspective integrating regulatory strategies and dispositional difficulties","volume":"82","author":"Samea","year":"2025","journal-title":"Sleep Med Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1017\/s0033291723002428","article-title":"The bidirectional association between psychiatric disorders and sheltered homelessness","volume":"54","author":"Nilsson","year":"2024","journal-title":"Psychol Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-2667(25)00100-8","article-title":"Homelessness, psychiatric disorders, and risks of suicide and self-harm: a population-based cohort study","volume":"10","author":"Nilsson","year":"2025","journal-title":"Lancet Public Health"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2011.183.1_meetingabstracts.a3087","article-title":"Efficacy of roflumilast in elderly patients with chronic obstructive pulmonary disease","volume":"183","author":"Hanania","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaclp.2025.06.002","article-title":"Examining the moderating effect of sex on the association between asthma and age of onset in bipolar disorder and schizophrenia","volume":"66","author":"Michel","year":"2025","journal-title":"J Acad Consult Liaison Psychiatry"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00031","article-title":"Salbutamol worsens the autonomic nervous system dysfunction of children with sickle cell disease","volume":"11","author":"Bokov","year":"2020","journal-title":"Front Physiol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2025.108074","article-title":"Efficacy of indacaterol vs tiotropium in COPD patients due to biomass exposure in improving quality of life and reducing symptoms","volume":"241","author":"Robles-Hern\u00e1ndez","year":"2025","journal-title":"Respir Med"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1836593\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:48:49Z","timestamp":1781156929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1836593\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":53,"alternative-id":["10.3389\/fpsyt.2026.1836593"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1836593","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"article-number":"1836593"}}